A needle enters the knee and removes a fragment of synovial tissue the size of a grain of rice. The pathologist examines it under a microscope, then classifies it: myeloid, lymphomyeloid, pauci-immune pathotype. Three labels that, in the next room, will decide whether the patient will receive a drug such as an anti-TNF or an anti-IL17. This is the proof-of-concept that Simone Parisi's group, from Turin, brought to London at EULAR 2026 to clarify…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
A needle enters the knee and removes a fragment of synovial tissue the size of a grain of rice. The pathologist examines it under a microscope, then classifies it: myeloid, lymphomyeloid, pauci-immune pathotype. Three labels that, in the next room, will decide whether the patient will receive a drug such as an anti-TNF or an anti-IL17. This is the proof-of-concept that Simone Parisi's group, from Turin, brought to London at EULAR 2026 to clarify…